Sito Bio: Subsidiary Srey Pharmaceuticals received the CEP certificate for Dexamethasone Sodium Phosphate raw materials

Zhitong
2025.10.09 11:45

Sito Bio announced that its holding subsidiary, Sray Pharmaceutical, recently received the European Pharmacopoeia suitability certificate for Dexamethasone Sodium Phosphate issued by the European Medicines Agency. The certificate is valid for five years starting from October 1, 2025. Dexamethasone Sodium Phosphate is a corticosteroid primarily used for allergic and autoimmune inflammatory diseases. According to IQVIA data, the global demand for Dexamethasone Sodium Phosphate raw materials is nearly 10 tons in 2024

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer